Epigenetics-targeted drugs: current paradigms and future challenges
Open accessThe DOI matches its Crossref record; 1,077 of the 1,077 references it cites were found in a registry or an index.
Abstract
Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA modification, histone modification, RNA modification, chromatin remodeling, and non-coding RNA regulation. These mechanisms and their associated enzymes convey genetic information independently of DNA base sequences, playing essential roles in organismal development and homeostasis. Conversely, disruptions in epigenetic landscapes critically influence the pathogenesis of various human diseases. This understanding has laid a robust theoretical groundwork for developing drugs that target epigenetics-modifying enzymes in pathological conditions. Over the past two decades, a growing array of small molecule drugs targeting epigenetic enzymes such as DNA methyltransferase, histone deacetylase, isocitrate dehydrogenase, and enhancer of zeste homolog 2, have been thoroughly investigated and implemented as therapeutic options, particularly in oncology. Additionally, numerous epigenetics-targeted drugs are undergoing clinical trials, offering promising prospects for clinical benefits. This review delineates the roles of epigenetics in physiological and pathological contexts and underscores pioneering studies on the discovery and clinical implementation of epigenetics-targeted drugs. These include inhibitors, agonists, degraders, and multitarget agents, aiming to identify practical challenges and promising avenues for future research. Ultimately, this review aims to deepen the understanding of epigenetics-oriented therapeutic strategies and their further application in clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 1,001–1,077 of 1,077
Zhang, Y., Lou, C., Xu, Y., Li, J., Qian, S., Li, F., & Kang, J. (2019) · Journal of Chromatography A · doi:10.1016/j.chroma.2019.460625 · Cited by 14
Smith, A. L., Skupa, S. A., Eiken, A. P., Reznicek, T. E., Schmitz, E. G., Williams, N., Moore, D. Y., D'Angelo, C. R., Kallam, A., Lunning, M. A., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.177054 · Cited by 14
Giansanti, M., Gabrieli, A. D., Prete, S. P., Ottone, T., Divona, M. D., Karimi, T., Ciccarone, F., Voso, M. T., Graziani, G., & Faraoni, I. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000537 · Cited by 13
Morris, J., Wishka, D. G., Lopez, O. D., Rudchenko, V. F., Huang, G., Hoffman, S. N., Borgel, S. D., Georgius, K., Carter, J., Stotler, H., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0738 · Cited by 13
Zhao, H., Lu, J., Tong, Y., Han, F., Sun, J., Yin, X., Cheng, L., Shen, C., Wunderlich, M., Yun, W., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110253 · Cited by 13
Hafez, H. M., Waz, S., El‐Tahawy, N. F. G., & Mohamed, M. Z. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116313 · Cited by 13
Gupta, V. K., Mascarenhas, J. O., Kremyanskaya, M., Rampal, R. K., Talpaz, M., Kiladjian, J., Vannucchi, A. M., Verstovšek, S., Colak, G., Dey, D., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010628 · Cited by 13
Ballinger, T. J., Marques, H. S., Xue, G. R., Hoffman, R. L., Gatsonis, C. G., Zhao, F., Miller, K. D., Sparano, J. A., & Connolly, R. M. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7045 · Cited by 13
Chen, L., Ren, A., Zhao, Y., Chen, H., Wu, Q., Zheng, M., Zhang, Z., Zhang, T., Wu, Z., Lin, J., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01513-6 · Cited by 13
Lee, V., Parkinson, R. M., ZAHURAK, M. L., Cope, L., Cercek, A., Verheul, H. M. W., Gootjes, E. C., Lenz, H. J., Iqbal, S., Jones, P. A., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34845 · Cited by 13
Xue, F., Liu, L., Tao, X., & Zhu, W. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2024.35.e64 · Cited by 13
Riddell, K., Patel, A. H., Collins, G. S., Zhou, Y., Schramek, D., Kremer, B. E., & Ferron‐Brady, G. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1711 · Cited by 12
Carraway, H. E., Sawalha, Y., Gojo, I., Lee, M.-J., Lee, S., Tomita, Y., Yuno, A., Greer, J., Smith, B. D., Pratz, K. W., et al. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106707 · Cited by 12
Heath, E. I., Weise, A. M., Vaishampayan, U. N., Danforth, D., Ungerleider, R. S., & Urata, Y. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01180-9 · Cited by 12
Hescheler, D. A., Hartmann, M. J. M., Riemann, B., Michel, M., Bruns, C. J., Alakus, H., & Chiapponi, C. (2022) · Cancers · doi:10.3390/cancers14112721 · Cited by 12
Identification of Selective BRD9 Inhibitor via Integrated Computational Approach
Ali, M. M., Ashraf, S., Nur‐e‐Alam, M., Qureshi, U., Khan, K. M., & Ul‐Haq, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113513 · Cited by 12
Selective BET inhibitor RVX ‐208 ameliorates periodontal inflammation and bone loss
Sun, M., Clayton, N., Alam, S., Asmussen, N. C., Wong, A. P., Kim, J. H., Luong, G., Mokhtari, S., Pellei, D. D., Carrico, C. K., et al. (2023) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13887 · Cited by 12
Cartwright, E., Slater, S., Saffery, C., Tran, A., Turkes, F., Smith, G. A., Aresu, M., Kohoutová, D., Terlizzo, M., Zhitkov, O., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102971 · Cited by 12
Modulators of histone demethylase JMJD1C selectively target leukemic stem cells
Yang, Y., Zhang, X., Zhang, X., Wang, Y., Wang, X., Hu, L., Zhao, Y., Wang, H., Wang, Z., Wang, H., et al. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.13054 · Cited by 11
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma
Nastoupil, L. J. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00617-5 · Cited by 11
Structural-Guided Identification of Small Molecule Inhibitor of UHRF1 Methyltransferase Activity
Awal, M. A., Nur, S. M., Khalaf, A. K. A., Rehan, M., Ahmad, A., Hosawi, S. B. I., Choudhry, H., & Khan, M. I. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.928884 · Cited by 11
Çalışkaner, Z. O. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-022-05297-3 · Cited by 11
Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer
Eickhoff, N., Bergman, A. M., & Zwart, W. T. (2022) · Endocrinology · doi:10.1210/endocr/bqac153 · Cited by 11
Komal, S., Gohar, A., Althobaiti, S., Khan, I. A., Cui, L.-G., Zhang, L., Han, S., & Shakeel, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1194311 · Cited by 11
Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse
Dennison, J. L., Mendez, A. J., Szeto, A., Lohse, I., Wahlestedt, C., & Volmar, C. (2023) · Biomolecules · doi:10.3390/biom13091324 · Cited by 11
Croucher, P. J. P., Ridinger, M., Becker, P. S., Lin, T. L., Silberman, S., Wang, E. S., & Zeidan, A. M. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05442-9 · Cited by 11
Unveiling the role of GAS41 in cancer progression
Ji, K., Li, L., Liu, H., Shen, Y., Jiang, J. D., Zhang, M., Teng, H., Yan, X., Zhang, Y., Cai, Y., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03098-z · Cited by 11
Tonozuka, Y., Tanaka, H., Nomura, K., Sakaguchi, K., Soeda, J., & Kakimoto, Y. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04609-5 · Cited by 11
Zakharia, Y., Singer, E. A., Acharyya, S., Garje, R., Joshi, M., Peace, D. J., Baladandayuthapani, V., Majumdar, A., Xiong, L., Lalancette, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45216-z · Cited by 11
Sergeeva, O. V., Akhmetova, E. A., Dukova, S., Beloglazkina, E. K., Uspenskaya, A. A., Machulkin, A. E., Stetsenko, D. A., & Zatsepin, T. S. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1342178 · Cited by 11
Jog, N. R., Wagner, C. A., Aberle, T., Chakravarty, E. F., Arriens, C., Guthridge, J. M., & James, J. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1339250 · Cited by 11
Li, L., Yang, W., Pan, Y., Ye, R., Wang, Y., Li, S., Jiang, H., Zhang, Q., Wang, X., & Yan, J. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2328227 · Cited by 11
A Brain Anti-Senescence Transcriptional Program Triggered by Hypothalamic-Derived Exosomal microRNAs
Krarup, J., Araya, L., Álvarez, F., Bórquez, D. A., & Urrutia, P. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105467 · Cited by 11
A sensitive protein-based sensor for quantifying histone acetylation levels
Sánchez, O. F., Williamson, D., Cai, L., & Yuan, C. (2015) · Talanta · doi:10.1016/j.talanta.2015.03.046 · Cited by 10
Brunvand, M. W., & Carson, J. (2017) · Hematological Oncology · doi:10.1002/hon.2421 · Cited by 10
Na, I., Choi, S., Son, S. H., Uversky, V. N., & Kim, C. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155248 · Cited by 10
Ten-eleven translocation protein 1 modulates medulloblastoma progression
Kim, H., Kang, Y., Li, Y., Chen, L., Lin, L., Johnson, N. D., Zhu, D., Robinson, M. H., McSwain, L., Barwick, B. G., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02352-9 · Cited by 10
Zhao, H., Li, D., Li, Q., Zhang, B., Xiao, C., Zhao, Y., Ge, J., Yu, Y., Jia, Y., Guo, X., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae033 · Cited by 10
Self-citationLahiri, D. K., Maloney, B., Wang, R., White, F. A., Sambamurti, K., Greig, N. H., & Counts, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102336 · Cited by 10
On RNA-programmable gene modulation as a versatile set of principles targeting muscular dystrophies
Capelletti, S., Soto, S. C. G., & Gonçalves, M. A. F. V. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.016 · Cited by 10
Bromodomain Inhibitors Modulate FcγR-Mediated Mononuclear Phagocyte Activation and Chemotaxis
Banham, G. D., Lee, C. Y. C., Ferdinand, J. R., Matthews, R. J., Jing, C., Smithers, N. N., Prinjha, R. K., & Clatworthy, M. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885101 · Cited by 9
Deng, K., Zou, Y., Zou, C., Wang, H., Xiang, Y., Yang, X., Yang, S. C., Cui, C., Yang, G., & Huang, J. M. (2022) · Cancer Medicine · doi:10.1002/cam4.5028 · Cited by 9
Prinz, F., Jonas, K., Balihodzic, A., Klec, C., Reicher, A., Barth, D. A., Riedl, J. M., Gerger, A., Kiesslich, T., Mayr, C., et al. (2022) · RNA Biology · doi:10.1080/15476286.2022.2152978 · Cited by 9
GB1a Activates SIRT6 to Regulate Lipid Metabolism in Mouse Primary Hepatocytes
Sun, Y., Zheng, C., Li, T., He, X., Yang, F., Guo, W., Song, J., Gao, Y., Deng, C., & Huang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119540 · Cited by 9
Self-citationGNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1
Cochran, A. G., & Flynn, M. E. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01149 · Cited by 9
Hong, W., Zhu, Y., Lin, Y., Tang, S., Chen, J., Xu, L., Jiang, J., Zong, Y., Zhang, Y., Sun, A., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122320 · Cited by 9
Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance
Llinas-Bertran, A., Bellet, M., & Seoane, J. A. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0282 · Cited by 9
Booth, S. W., Eyre, T. A., Whittaker, J. A., Campo, L., Wang, L. M., Soilleux, E. J., Royston, D. J., Rees, G., Kesavan, M., Hildyard, C., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08595-w · Cited by 8
Wang, T., Shen, G., Li, J., Huo, X., Wang, M., Liu, Z., Zhao, F., Ren, D., & Zhao, J. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230407101128 · Cited by 8
Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma
Bitler, B. G., Bailey, C. A., Yamamoto, T. M., McMellen, A. N., Kim, H., & Watson, Z. L. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23610 · Cited by 8
Reading and erasing of histone crotonyllysine mimics by the AF9 YEATS domain and SIRT2 deacylase
Bilgin, N., Türkmen, V. A., Hammami, N., Christensen, N. R., Hintzen, J. C. J., & Mecinović, J. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117500 · Cited by 8
SETDB1: Progress and prospects in cancer treatment potential and inhibitor research
Ma, T., Xu, F., Hou, Y., Shu, Y., Zhao, Z., Zhang, Y., Bai, L., Lu, F., & Zhong, L. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107219 · Cited by 8
Enhancing anticancer activity of macrophages through rational drug combinations
Mills, G. B., & Labrie, M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180512 · Cited by 8
Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy
Ma, S., Long, G., Jiang, Z., Zhang, Y., Sun, L., Pan, Y., You, Q., & Guo, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116532 · Cited by 8
Marques-Magalhães, Â., Graça, I. C. R., Miranda‐Gonçalves, V., Henrique, R., Lopez, M., Arimondo, P. B., & Jerónimo, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111681 · Cited by 7
Fragment-Based Discovery of AF9 YEATS Domain Inhibitors
Liu, Y., Jin, R., Lu, H., Bian, K., Wang, R., Wang, L., Gao, R., Zhang, J., Wu, J., Yao, X., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073893 · Cited by 7
PEGR: a flexible management platform for reproducible epigenomic and genomic research
Shao, D., Kellogg, G. D., Nematbakhsh, A., Kuntala, P. K., Mahony, S., Pugh, B. F., & Lai, W. (2022) · Genome biology · doi:10.1186/s13059-022-02671-5 · Cited by 7
Koh, E. S., Kim, S., Son, M., Park, J., Pyo, J., Kim, W., Kim, M., Chung, S., Park, C. W., Kim, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214045 · Cited by 7
Ovadia, S., Cui, G., Elkon, R., Cohen-Gulkar, M., Zuk-Bar, N., Tuoc, T., Jing, N., & Ashery‐Padan, R. (2023) · Development · doi:10.1242/dev.201488 · Cited by 7
Zhou, S., Zhang, Q., Yang, H., Zhu, Y., Hu, X., Wan, G., & Yu, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122538 · Cited by 7
Yang, Y., Ahmad, E., Premkumar, V., Liu, A., Rahman, S. A., & Nikolovska‐Coleska, Z. (2024) · Protein Science · doi:10.1002/pro.5019 · Cited by 7
Enasidenib Approved for AML, but Best Uses Unclear
(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-117 · Cited by 6
Xue, C., Xu, Z., Liu, Z., et al. (2023) · The Chinese Journal of Physiology · doi:10.4103/cjop.cjop-d-22-00118 · Cited by 6
Chen, F., Li, M., Hua, Z., Ren, H., Luo, A., Gu, H., Zhou, C., Zhu, Z., Huang, T., & Bi, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512455 · Cited by 6
Chen, H., Xiao, L., Xie, G., Zhang, P., Dong, P., Bian, B., Wang, J., Zhou, Y., Ma, Y., Liu, Y., et al. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23662 · Cited by 6
Pliability in the m6A-Binding Region Extends Druggability of YTH Domains
Cazzanelli, G., Vedove, A. D., Spagnolli, G., Terruzzi, L., Colasurdo, E., Boldrini, A., Patsilinakos, A., Sturlese, M., Grottesi, A., Biasini, E., et al. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00051 · Cited by 6
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review
Viviano, M., Cipriano, A., Fabbrizi, E., Feoli, A., Castellano, S., Sbardella, G., Mai, A., Milite, C., & Rotili, D. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327300 · Cited by 6
Bromodomain inhibition targeting BPTF in the treatment of melanoma and other solid tumors
Khan, I., & Kashani–Sabet, M. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-024-10265-7 · Cited by 6
Moral‐Morales, A. D., Salgado-Albarrán, M., Ortiz-Gutiérrez, E., Pérez‐Hernández, G., & Soto‐Reyes, E. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.860924 · Cited by 5
Epigenetic and pharmacological control of pigmentation via Bromodomain Protein 9 ( BRD9 )
Basuroy, T., Dreier, M. R., Baum, C. E., Blomquist, T. M., Trumbly, R. J., Filipp, F. V., & de la Serna, I. L. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13068 · Cited by 5
Peptides Derived from Histone 3 and Modified at Position 18 Inhibit Histone Demethylase KDM6 Enzymes
Jones, S. E., Olsen, L., Dorosz, J., Seger, S. T., Andersson, J., Kristensen, L. H., & Gajhede, M. (2018) · ChemBioChem · doi:10.1002/cbic.201800185 · Cited by 4
Zhang, W., Ning, R., Ran, T., Qi, P., Liu, Y., Lu, T., Chen, Y., Jiang, M., & Jiao, Y. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117440 · Cited by 4
MBD4: guardian of the epigenetic galaxy
Busque, L., & Godley, L. A. (2018) · Blood · doi:10.1182/blood-2018-08-867044 · Cited by 3
Lin, T., Engelhard, L., Söldner, B., Linser, R., & Summerer, D. (2024) · Advanced Science · doi:10.1002/advs.202307930 · Cited by 3
Wu, X., Meng, Y., Chen, J., Zhang, Y., & Xu, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122578 · Cited by 3
Pandey, K., Acharya, A., Pal, D., Jain, P., Singh, K. D., Durden, D. L., Kutateladze, T. G., Deshpande, A. J., & Byrareddy, S. N. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105904 · Cited by 3
Wasiak, S., Fu, L., Daze, E., Gilham, D., Rakai, B. D., Stotz, S. C., Tsujikawa, L. M., Sarsons, C. D., Studer, D., Rinker, K. D., et al. (2023) · Translational Neuroscience · doi:10.1515/tnsci-2022-0332 · Cited by 2
Cited by
Age reprogramming: Innovations and ethical considerations for prolonged longevity (Review)
Saliev, T., & Singh, P. (2025) · Biomedical Reports · doi:10.3892/br.2025.1974 · Cited by 14
Metadata
- Authors
- Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., Xiao, X., & Li, D.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-11-26
- Volume
- 9
- Issue
- 1
- Pages
- 332-332
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4404726166
- Cited by
- 339
- References
- 1,077
- FWCI
- 39.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.